A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).
Genomic testing based on chromosome microarray (CMA) and Next Generation Sequencing (NGS) revolutionized clinical genetics. That said, microarray, targeted panel, exome and generic whole genome ...
Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.
Bionano Genomics and Greenwood Genetic Center have announced a study published in Genome Research, marking the first use of optical genome mapping (OGM) to explore the genetic factors behind neural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback